D-Mannose sustained-release preparation U-Clear PRO is a low-endotoxin, crystalline pharma-grade API supplied with controlled particle-size distribution for oral solid-dose and injectable development. Because D-mannose is a reducing hexose with high aqueous solubility, its formulation behaviour is dominated by particle attrition, moisture management, and dissolution-rate modification rather than solubility enhancement. The following application scenarios are limited to dosage configurations with established or emerging technical precedent.

Where D-mannose is intended for oral sustained-release prophylaxis of recurrent uncomplicated urinary tract infection, the most technically defensible starting point is a hydrophilic matrix tablet rather than an immediate-release coated form. In this configuration, the API is charged at 55–70% w/w of the core mass, with a 1000 mg core carrying approximately 600–700 mg D-mannose. The remaining mass is divided between high-viscosity hydroxypropyl methylcellulose HPMC K100M at 18–25% w/w and microcrystalline cellulose at 10–20% w/w, with sodium stearyl fumarate at 1.5% w/w and colloidal silicon dioxide at 0.5% w/w. The choice of HPMC K100M is not arbitrary: below 15% w/w HPMC K100M the matrix cannot maintain gel-layer continuity at high D-mannose loading, and dissolution shifts from diffusion-controlled to erosion-dominated release, producing an observed burst above 40% release within the first hour in USP <711> Apparatus 2 testing. Above 25% w/w, the hydrated gel becomes mechanically resistant enough to suppress late-stage core erosion, but tablet hardness and ejection force become problematic on high-speed rotary presses.

Compliance boundaries are defined by both finished-article monographs and site quality systems. For products placed on the United States market as dietary supplements, 21 CFR 111 cGMP applies; for drug listings, 21 CFR 211 applies. Regardless of classification, release testing is anchored to USP <711> for dissolution, USP <2091> for weight variation, and USP <2040> for disintegration where disintegration testing remains meaningful. The API itself is controlled under the USP-NF D-Mannose monograph, with assay not less than 98.0% and not more than 102.0% on the dried basis, loss on drying not more than 0.5%, and residue on ignition not more than 0.1%. Residual solvent control follows USP <467>; elemental impurities are assessed against ICH Q3D PDE limits.

Downstream manufacturing uses high-shear wet granulation followed by fluid-bed drying. D-mannose, HPMC K100M, and microcrystalline cellulose are dry-mixed in a 300 L high-shear granulator at impeller speed 120–180 rpm and chopper speed 1500 rpm for 2 min; purified water or a 2–4% w/w povidone K30 solution is sprayed over 3–5 min until the granule endpoint is characterised by a slightly plastic mass without large snowballs. The wet mass is passed through a 4 mm screen and dried in a fluid-bed dryer with inlet air at 55–65°C until loss on drying falls below 2.0%. Dried granules are milled through a 0.8 mm conical screen at 1000–1500 rpm, then blended with sodium stearyl fumarate and colloidal silicon dioxide in a bin blender at 12–15 rpm for 3 min. Compression is carried out on a 45-station rotary tablet press with pre-compression force 5 kN and main compression force 15–22 kN, turret speed 25–45 rpm. Target hardness is 8–12 kp, friability below 0.3%, and mean weight variation below 2.0%. Film coating with Opadry II at 3.0% weight gain is applied in a 48-inch perforated pan coater with inlet temperature 60–70°C, bed temperature 38–45°C, spray rate 80–120 g/min, atomising air pressure 1.5–2.0 bar, and pan speed 6–12 rpm.

The finished article is a film-coated sustained-release tablet of 500 mg or 1000 mg D-mannose, packed in HDPE bottles with silica-gel desiccant and induction-sealed closures. The desiccant is essential because high ambient humidity above 60% RH during prolonged storage raises water activity inside the HPMC matrix and accelerates polymer relaxation, shifting the release profile forward by up to 15% at the same sampling time.

What Direct Compression Parameters Counteract Low Tensile Strength in D-Mannose Capsule Blends?

Hard-shell capsule dosage configurations require a blend with sufficient flow and compactability for high-speed encapsulation, but crystalline D-mannose alone exhibits poor tensile strength and may produce capping during slugging. The formulation window therefore relies on high-fill silicified microcrystalline cellulose and low-dust pre-blending. D-mannose is incorporated at 60–75% w/w, silicified microcrystalline cellulose at 20–30% w/w, croscarmellose sodium at 2–4% w/w, colloidal silicon dioxide at 0.25–0.5% w/w, and magnesium stearate at 0.5–1.0% w/w. The silicified MCC acts as both filler and flow modifier; croscarmellose sodium is retained at the lower end of its typical range because D-mannose dissolution is not rate-limiting and excessive wicking tends to increase weight variability on rotary encapsulators.

Compliance for this configuration is governed by USP <2091> weight variation, USP <2040> disintegration for hard capsules, and 21 CFR 111 or 21 CFR 211 depending on market pathway. For European markets, Ph.Eur. 2.9.5 uniformity of mass and Ph.Eur. 2.9.1 disintegration apply. Elemental impurities are aligned to ICH Q3D. Where vegetarian capsules are specified, the shell itself must meet pharmacopoeial non-gelatin capsule requirements, and dissolution testing should be performed with sinkers to prevent capsule shell buoyancy artifacts.

Downstream processing begins with screening of D-mannose and silicified MCC through a 30-mesh sieve to remove soft agglomerates. The blend is charged into a 500 L V-blender and mixed at 15 rpm for 20 min; magnesium stearate is then added through a 0.7 mm screen and blended for an additional 2–3 min. Encapsulation is performed on a rotary capsule machine equipped with a size 0 or size 00 dosing disc, depending on whether the target fill is 500 mg or 750 mg D-mannose. Tamping force is maintained at 0.25–0.35 kN; lower tamping force produces under-filled capsules, while higher force compacts the powder bed and creates ejection torque variability. Weight variation is monitored at ±3.0% for individual capsules, with average weight within ±2.0% of target. The finished article is a two-piece HPMC vegetarian hard capsule of 500 mg or 1000 mg D-mannose, packed in bulk HDPE drums or push-through blisters.

Effervescent oral granules containing D-mannose are manufactured under dry granulation because any residual moisture introduced during wet massing will trigger premature citric acid–sodium bicarbonate reaction inside the granulator. The addition ratio in a single-dose sachet is typically 45–60% w/w D-mannose, 18–25% w/w anhydrous citric acid, 15–20% w/w sodium bicarbonate, 3–5% w/w polyethylene glycol 6000, and 2–5% w/w flavour and flow aids. The presence of D-mannose as the major soluble component contributes both sweetness and osmotic activity; sodium bicarbonate and citric acid are balanced to produce a pH of 4.5–5.5 after reconstitution in 200 mL water, which is palatable without compromising D-mannose stability in solution for immediate consumption.

Compliance is aligned to 21 CFR 111 for dietary supplement cGMP and, where applicable, effervescent monograph expectations of USP <2040>. For effervescent products, disintegration testing is performed in 250 mL purified water at 20–25°C; the entire sachet content should dissolve or disperse within 3 min without leaving insoluble residue. Residual moisture is critical: the in-process limit for free moisture in the final granulation is below 0.8% by Karl Fischer titration, and packaging is conducted below 20% RH in a dehumidified suite.

Manufacture is carried out by roller compaction at hydraulic pressure 20–40 kN/cm, using a roll speed of 5–10 rpm and a granulator mesh of 0.8–1.6 mm. Ribbon density is monitored continuously; flakes outside 0.85–1.15 g/cm³ are re-milled and re-compacted, which must not exceed 15% of total batch mass to avoid reducing carbonate potency. The granulation is discharged into vertical form-fill-seal stick-pack machines operating at 80–120 packs/min; each sachet is dosed by auger filler with weight tolerance ±3.0%. Sealing temperature is 130–160°C on aluminium-foil laminate. The terminal finished product is a single-dose effervescent granule sachet containing 2000 mg D-mannose, packed in foil pouches or cartons with desiccant packs in the outer carton.

Aseptic Injectable D-Mannose: Filtration, Osmolarity, and Terminal Sterilisation Boundaries

Injectable D-mannose is an emerging route rather than a broadly codified compendial configuration, and published data for this specific configuration is limited. Where an injectable grade is specified, the formulation must be developed as a sterile, pyrogen-free aqueous solution. A starting addition ratio is 5.0–10.0% w/v D-mannose in water for injection, with sodium chloride added as needed to achieve osmolarity 280–320 mOsmol/L. pH is adjusted to 5.0–7.5 with 0.1 N hydrochloric acid or sodium hydroxide. Because D-mannose is a reducing sugar, the solution should not be held at elevated temperature for extended periods before sterilisation; hold time from dissolution to terminal sterilisation is limited to 8 h at 2–8°C, and the thermal sterilisation cycle should be a validated moist-heat cycle at 121°C for 15 min, equivalent to F0 ≥12 min, rather than an aggressive 134°C cycle that may increase 5-hydroxymethylfurfural formation.

Process operations begin by adding D-mannose to 80% of the final volume of water for injection at 40–50°C under low-shear mixing, then cooling to 20–25°C before pH adjustment and volume make-up. The solution is passed through a 0.45 µm prefilter and then a 0.22 µm PVDF sterilising filter under aseptic conditions. Filling is performed in a Grade A unidirectional airflow zone with Grade B background into Type I glass vials or infusion bottles. Terminal sterilisation is conducted after sealing. In-process bioburden before filtration is controlled below 10 CFU/100 mL; the API supplier must provide a bacterial endotoxin specification not higher than 0.25 EU/mg, a requirement that exceeds typical oral-grade D-mannose specifications and must be confirmed with each lot.

Compliance is anchored to Ph.Eur. 2.6.14 bacterial endotoxins, Ph.Eur. 2.6.1 sterility, USP <1> Injections, USP <85> bacterial endotoxins test, USP <787> subvisible particulate matter, and ICH Q3D elemental impurities for parenteral products. The finished article is a sterile injectable solution of 50 mg/mL or 100 mg/mL D-mannose in 10 mL or 50 mL vials, intended for compounding or licensed prescription use only after local regulatory authorisation has been obtained.

When D-Mannose Oral Granules Are Spray-Granulated, Binder Viscosity Governs Fines Distribution

Direct-consume oral granules in single-dose sachets present a narrower particle-size specification than granules intended for compression, and the top-spray fluid-bed process is selected because it produces low-dust, free-flowing granules with minimal attrition. D-mannose is charged at 75–85% w/w, with povidone K30 as binder at 2–4% w/w, mannitol at 10–15% w/w, sucralose at 0.1–0.3% w/w, and a flavour system at 1–3% w/w. The binder is prepared as a 5–7% w/w aqueous povidone solution; viscosity of the binder solution is kept below 50 mPa·s at 25°C because higher viscosity lowers the atomisation droplet size distribution and creates coarse, uneven granules with elevated fines when the spray rate is held constant.

Compliance is governed by USP <2091> weight variation for powders packaged in unit-dose containers, USP <2040> where a dispersion test is relevant, and 21 CFR 111 or 211. The granule moisture specification is set at 1.5–2.5% by loss on drying; above 2.5% the granules agglomerate in the sachet and below 1.0% electrostatic charging increases fill-weight drift during packaging. Sieve analysis is controlled with not more than 15% fines below 150 µm and not more than 10% oversized above 2000 µm.

Processing occurs in a top-spray fluid-bed granulator with inlet air temperature 60–70°C, product temperature 32–38°C, atomising air pressure 2.0–2.5 bar, and spray rate 20–40 g/min per kg of dry charge. The endpoint is determined by granule loss on drying and by observing the bed movement on the sight glass: the granules should transition from a dense saltation pattern to a smooth fountain within 2–3 min after the spray phase ends. Dried granules are sieved through a 1.0–2.0 mm oscillating screen and filled into stick packs at 70–100 packs/min with auger dosing. The terminal finished product is a direct-consume oral granule sachet of 2000 mg D-mannose, sealed in moisture-barrier laminate.

Extruding and Spheronising D-Mannose Multiparticulates for Extended-Release Capsule Fill

Multiparticulate capsules are selected when the pharmacokinetic objective is to avoid a single matrix tablet and deliver dose-splitting across multiple pellets. D-mannose is granulated into dense cores by extrusion-spheronisation, then coated with a release-modifying membrane. The core formulation contains 60–70% w/w D-mannose, 20–30% w/w microcrystalline cellulose, 5–10% w/w lactose monohydrate, and 2–5% w/w hydroxypropyl methylcellulose as a spheronisation aid. Water is added during the wet massing step to a final moisture content of 25–35% w/w. The wet mass must show a cohesive plastic character without sticking to the extruder barrel; insufficient water produces high torque and irregular pellet shapes, while excess water creates pellets that fuse during spheronisation.

Release control is achieved with a 10–15% w/w coating of ethylcellulose aqueous dispersion applied to the dried cores. Below 10% weight gain, coating thickness is too heterogeneous to prevent immediate release from small pellets; above 15%, the release lag becomes overly dependent on curing temperature and the pellet surface may develop cracks during capsule filling. The coated pellets are cured in a fluid-bed dryer at 40–60°C for 2 h to complete coalescence of the ethylcellulose membrane. Dissolution testing is performed in USP Apparatus 1 at 100 rpm in 900 mL phosphate buffer pH 6.8, with sampling at 1 h, 4 h, and 12 h to confirm that the sustained-release profile falls within the same diffusion-controlled window as the matrix tablet but with lower inter-tablet variability.

Compliance anchors include USP <711>, Ph.Eur. 2.9.3, USP <2091> for capsule weight variation, and ICH Q3D. The terminal product is a hard gelatin or HPMC capsule filled with sustained-release D-mannose pellets at a fill weight adjusted to deliver 500 mg or 1000 mg D-mannose, suitable for twice-daily dosing after meals. Published data for this specific configuration is limited; the described ranges are development starting points that must be verified against API lot-to-lot particle size and humidity history.